Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
【US Stock Movement】Robinhood Markets plunged on October 14: Target price lowered, crypto stocks weakened, and rising interest rates

【US Stock Movement】Robinhood Markets plunged on October 14: Target price lowered, crypto stocks weakened, and rising interest rates

Bitget异动解读Bitget异动解读2026/10/14 15:21
Show original

Robinhood Markets October 14 Sell-off Analysis

Keywords: Target Price Downgrade, Weak Crypto Stocks, Rising Interest Rates

1. On October 14, Wells Fargo lowered Robinhood's target price from $125 to $120 while maintaining a Hold rating, indicating a revision of sell-side valuation expectations.

2. On October 14, US-listed cryptocurrency-related stocks generally weakened; at the same time, the US September CPI exceeded expectations and Treasury yields rose, putting pressure on highly valued tech stocks. The weakness in related sectors dragged down Robinhood.

(Disclaimer: This content is summarized from publicly available information collected using AI technology and is for reference only. It does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%